BeStock  
Stocks › Biotechnology › GMAB

Genmab GMAB

US equityMarket cap rank #628Biotechnology
$50.60 −$0.75 (-1.46%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $50.02 -1.15%
Open$51.57
Prev close$51.35
Day range$50.24 – $51.72
Volume2.90M
Market cap$31.20B
P/E (TTM)43.2
Dividend yield–

GMAB Stock News

Headlines matching Genmab or the GMAB ticker, most recent first.

  • H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $40Market news · 14 Sep 2026 · Direct mention
  • A Quick Look at Today's Ratings for Genmab(GMAB.US), With a Forecast Between $35 to $43Market news · 8 Aug 2026 · Direct mention
  • William Blair Maintains Genmab(GMAB.US) With Buy RatingMarket news · 12 Aug 2026 · Direct mention
  • Truist Financial Maintains Genmab(GMAB.US) With Buy RatingMarket news · 12 Aug 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Definitive Healthcare Corp (DH) and Atai Beckley N.V. (ATAI)TipRanks · 12 Aug 2026 · Direct mention
  • Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $33Market news · 23 Jul 2026 · Direct mention
  • TD Cowen Upgrades Genmab(GMAB.US) to Buy Rating, Raises Target Price to $43 PositiveMarket news · 22 Jul 2026 · Direct mention
  • H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Raises Target Price to $40 PositiveMarket news · 2 Jul 2026 · Direct mention
  • TD Cowen Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $32Market news · 13 Jul 2026 · Direct mention
  • A Quick Look at Today's Ratings for Genmab(GMAB.US), With a Forecast Between $40 to $40Market news · 30 Jun 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: Genmab (GMAB) and Hinge Health, Inc. Class A (HNGE)TipRanks · 30 Jun 2026 · Direct mention
  • H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $38Market news · 23 Jun 2026 · Direct mention
  • Wells Fargo Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $40Market news · 2 Jun 2026 · Direct mention
  • Wolfe Research Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $32Market news · 15 Jun 2026 · Direct mention
  • Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Cuts Target Price to $33 NegativeMarket news · 8 May 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on GMAB.

Sign in to join the discussion.

Scroll to Top